retatrutide 2025 trial results Phase 3: 60% Achieved Surgical-Level Weight Loss Lilly's triple agonist, retatrutide, delivered

Mild symptoms that gradually become easier to manage are different from repeated vomiting, progressive abdominal pain, or gastrointestinal problems that make it difficult to drink enough fluid

As for significant weight management results, those tend to show up after a few months of consistent effort

In-clinic labs only

The consultation reviews your health history, goals, current medications, and determines whether GLP-1 therapy is appropriate for you

The expected timeline: Phase 3 trials completing: Results rolling out throughout the rest of this year FDA submission: Expected sometime after full Phase 3 data is available Potential FDA approval: Estimated for late 2027 at the earliest Commercial availability: If approved, launch would follow in 2027-2028 For those tracking retatrutide availability updates , the situation is evolving

If you have not had bloodwork done recently, schedule it before your GLP-1 appointment